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Abstract
Background: When a test for diagnosis of infectious diseases is introduced in a resource-limited
setting, monitoring quality is a major concern. An optimized design of experiment and statistical
models are required for this assessment.
Methods: Interferon-gamma release assay to detect tuberculosis (TB) infection from whole blood
was tested in Hanoi, Viet Nam. Balanced incomplete block design (BIBD) was planned and fixed-
effect models with heterogeneous error variance were used for analysis. In the first trial, the whole
blood from 12 donors was incubated with nil, TB-specific antigens or mitogen. In 72 measurements,
two laboratory members exchanged their roles in harvesting plasma and testing for interferon-
gamma release using enzyme linked immunosorbent assay (ELISA) technique. After intervention
including checkup of all steps and standard operation procedures, the second trial was
implemented in a similar manner.
Results: The lack of precision in the first trial was clearly demonstrated. Large within-individual
error was significantly affected by both harvester and ELISA operator, indicating that both of the
steps had problems. After the intervention, overall within-individual error was significantly reduced
(P < 0.0001) and error variance was no longer affected by laboratory personnel in charge, indicating
that a marked improvement could be objectively observed.
Conclusion: BIBD and analysis of fixed-effect models with heterogeneous variance are suitable
and useful for objective and individualized assessment of proficiency in a multistep diagnostic test
for infectious diseases in a resource-constrained laboratory. The action plan based on our findings
would be worth considering when monitoring for internal quality control is difficult on site.
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Background
Assuring quality is essential for clinical laboratories in the
field of infectious diseases. Beneficiaries are not only
patients obtaining a diagnosis on site but also future
patients receiving benefits of clinical research supported
by qualified laboratories. Quality assurance in modern
laboratories is realized by total quality management
including external quality assurance (EQA) and internal
quality control (IQC) [1-3].
In most resource-constrained countries, however, regula-
tions on quality assurance have not been laid down by the
authorities and accuracy and precision of clinical meas-
urements have not been monitored systematically [4].
Under such disadvantageous circumstances, when impor-
tant but rather complicated testing for infectious diseases
is undertaken, we cannot easily be confident that the skill
has been transferred and maintained properly until the
procedure becomes familiar and stably performed in
accordance with a desirable quality control system [5].
During this vulnerable period, how to assess proficiency
of the testing effectively and objectively, and how to
assure and improve the quality are open issues to be
addressed.
Currently, immunoassay is commonly used to make a
serological diagnosis of infectious diseases involving
human immunodeficiency virus, a variety of hepatitis
virus and other sexually transmitted or blood-borne path-
ogens [6,7], which are serious problems in the developing
world. Enzyme linked immunosorbent assay (ELISA) is
often used to make diagnosis of these diseases in the clin-
ical laboratories. Because of the complexity of the
method, however, quality control of these assay systems is
challenging [8]. In this context, trend of point of care
(POC) tests that facilitate immediate and on-site diagno-
sis as well as early treatment of infectious diseases has
been emphasized [7]. However, their usage in resource-
constrained countries is still hampered by high cost and
difficulties in testing for high throughput screening and
thus laboratory-based immunoassays would be irreplace-
able in many fields.
Recently, a two-step immunoassay to detect tuberculosis
(TB) infection has also been developed and used exten-
sively [9]. It consists of whole blood stimulation with TB-
specific antigens followed by measurement of interferon-
gamma using ELISA. Our objective in the present study is
to demonstrate that the quality of laboratory tests can be
assessed objectively even in a resource-constrained labo-
ratory if the optimum design of experiments and appro-
priate statistical models are chosen. As a result of this
attempt, we experienced marked improvement of the
quality of this multi-step immunoassay made by more
than one laboratory staff member in a hospital of Viet
Nam. We proposed a general plan to evaluate skills of lab-
oratory staff members efficiently and quantitatively to
perform qualified immuno-diagnostic testing especially
for infectious diseases until such time as they establish a
total quality management system by themselves.
Methods
Interferon-gamma release assay (IGRA) for diagnosis of TB 
infection
IGRA is a general method to measure interferon-gamma
induced by Mycobacterium tuberculosis-specific antigens
(TB-Antigen) for detecting TB infection. In the ELISA-
based IGRA (QuantiFERON-TB Gold In-Tube™, Cellestis,
Victoria, Australia), one milliliter of the whole blood was
collected into the Nil tube for negative control, Mitogen
for positive control, and TB-Antigen separately. The blood
in the tubes was mixed and placed in the incubator for 18
hours at 37°C (Cool incubator NC-25B, Funakoshi,
Tokyo, Japan). Approximately 200 μl of plasma were har-
vested from each tube after centrifugation (Kubota 2010,
Kubota, Tokyo, Japan).
Interferon-gamma concentrations in the plasma were
measured by ELISA, using microtiter plate washer and
reader (Wellwash Plus Microplate Washer and Multiscan
JX Microplate Reader, Thermo Electron Corporation, Van-
taa, Finland) with the analysis software provided by the
manufacturer (QuantiFERON-TB Gold Analysis Software,
ver. 2.50, Cellestis). In this study, interferon-gamma con-
centrations obtained from this calculation were directly
used for further analysis.
Study setting
Two trials were carried out in Hanoi TB and Lung Disease
Hospital, Viet Nam. Between the first and second trial, sta-
tistical analysis was made and an intervention was
planned to ensure counterchecking and correct question-
able manipulations. Each trial consisted of two runs. In
each run, three milliliters of blood were collected from
volunteers after informed consent had been obtained.
Study protocols using IGRA were approved by ethical
committees of the Ministry of Health, Viet Nam and Inter-
national Medical Center of Japan respectively.
Two laboratory members, A and B, performed either
plasma harvest or ELISA operation or both: Harvest
included labeling and placing plasma storage tubes prop-
erly and transferring plasma from centrifuged blood col-
lection tubes to these tubes by pipetting. ELISA was a
process including preparing reagents and transferring
plasma samples into the microtiter plate. ELISA ended
with calculation of interferon-gamma concentration.
Because their roles were changed occasionally due to the
limited manpower of the laboratory, their performance in
both Harvest and ELISA was the subject to be analyzed.BMC Infectious Diseases 2009, 9:66 http://www.biomedcentral.com/1471-2334/9/66
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Balanced incomplete block design (BIBD)
A single specimen obtained from routine blood collection
was not sufficient to assess two staff members' perform-
ance. Because additional blood sampling was not easily
accepted in many countries including Viet Nam, BIBD was
attempted to obtain analytical information from small
volume of plasma samples in this study: Of four possible
combinations of harvester and ELISA operator, two com-
binations were cyclically chosen, using the limited
amount of specimen. Allocation of observed combina-
tions by BIBD in this study was described in Table 1. In
each trial, there were two levels of Harvest (two different
Harvesters), two levels of ELISA (two different ELISA oper-
ators) and 12 levels of Specimen (12 different blood
donors).
Outliers
To identify outliers, Mahalanobis distance D was calcu-
lated, which took the distance from the mean and correla-
tion into account [10]. When D > 2.0, the value of that
observed pair was regarded as outlier.
A fixed-effect model and three-way analysis of variance 
(ANOVA)
To assess effects of factors of interest and error variance,
we used a fixed-effect model:
of which,
yijk: Interferon-gamma concentration in the plasma
μ: Grand mean of all measurements
αi: Harvest with i levels: i = 1, 2 (= A and B)
βj: ELISA with j levels: j = 1, 2 (= A and B)
γk: Blood specimen with k levels: k = 1, 2,..., 12
εijk: Within-individual error; following normal distribu-
tion with mean = 0 and variance = σ2: N (0, σ2)
In this clinical setting, effects of interaction terms were not
considered in the above model, because harvesting
plasma and performing ELISA are independent steps and
it is unlikely that the exchanging of staff roles in itself
could increase the chances of error.
Analysis of heterogeneous error variance affected by a 
given factor
To determine whether individuals of Harvest or ELISA
affect within-individual error, we assessed a fixed-effect
model with heterogeneous variance of error in the follow-
ing way:
where error follows the normal distribution N(0, σij
2).
Error variance affected by Harvesters was evaluated in the
following formula:
Similarly, the following formula was used for error vari-
ance affected by ELISA operators:
Coefficient of variation (CV) before and after intervention
Error variance εijk that included sources of Harvest and
ELISA was calculated in a simple one-way ANOVA model
adjusted by specimen. Based on the following formula,
CVs of the two trials were assessed:
yijk i j k ijk =+ + + + μα β γ ε
yijk i j k ij =+ + + + μα β γ ε
yijk i j k i. =+ + + + μα β γ ε
yijk i j k .j =+ + + + μα β γ ε
y ki j k =+ + μγ ε
Table 1: Allocation of observed combinations of Harvester and ELISA operator.
Sample Specimen* Harvest ELISA Data Sample Specimen Harvest ELISA Data
1 1 A A Observed 7 4 A A Observed
2 1 A B Observed 4 A B Not observed
1 B A Not observed 8 4 B A Observed
1 B B Not observed 4 B B Not observed
2 A A Not observed 5 A A Not observed
2 A B Not observed 9 5 A B Observed
3 2 B A Observed 5 B A Not observed
4 2 B B Observed 10 5 B B Observed
5 3 A A Observed 6 A A Not observed
3 A B Not observed 11 6 A B Observed
3 B A Not observed 12 6 B A Observed
6 3 B B Observed 6 B B Not observed
*To each specimen, two measurements were assigned. This layout was repeated twice by using different sets of specimens in each trial.BMC Infectious Diseases 2009, 9:66 http://www.biomedcentral.com/1471-2334/9/66
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CV should not be larger than 20% in any types of immu-
noassay [8].
Assessment of heterogeneous variance between the two 
trials
To analyze overall within-individual error between the
two trials statistically, we used a fixed-effect model with
heterogeneous variance of error, under the assumption
that α and β were fixed throughout the trials. The effect of
each blood specimen γ was expected to be different
between the two trials.
of which, εijk1 and εijk2 were within-individual errors of the
first and the second trial respectively. On the above
assumption, εijk1 and εijk2 would be heterogeneous error
between the trials.
Calculation of Mahalanobis distance, three-way ANOVA
and estimation of heterogeneous variance were per-
formed by SAS version 9.1 (SAS Institute Cary, NC, USA).
Differences in error variance of two trials and error vari-
ance affected by a given factor were considered to be sig-
nificant when P-value was less than 0.05.
Results
Evaluation of outliers and three-way ANOVA in the first 
trial
Out of 72 measurements obtained from the first trial,
seven outliers were identified: One was in Nil condition,
three in TB-Antigen and three in Mitogen (Mahalanobis D
= 2.64 to 4.69).
To assess effects of individuals for Harvest and ELISA and
character of errors involved in the first trial, we first per-
formed three-way ANOVA using a fixed-effect model, in
which three factors, Harvest, ELISA and individual blood
specimens may have possible effects on the interferon-
gamma concentration respectively. This model decom-
poses the total variance into between-individual error (or
bias) and within-individual error (or imprecision).
Herein, "between-individual error" indicates deviation in
interferon-gamma values caused by the difference
between Harvesters or ELISA operators, and "within-indi-
vidual error" represents fluctuation of interferon-gamma
values measured by a single Harvester or ELISA operator.
As shown in Table 2, mean square error indicating magni-
tude of within-individual error was large in all conditions
of the first trial, which was indicated by remarkably large
CV (> 20%) for Nil, TB-Antigen and Mitogen. Further-
more, in the condition of Mitogen, the mean-square value
directing the effect of ELISA, or "between-individual
error", was significantly large (P = 0.017). In the other two
conditions, the effects of ELISA and Harvest were also con-
siderably large but did not reach significant levels, as com-
pared with the corresponding mean square errors. These
findings indicate that their performance is unstable. Prob-
lems specific to ELISA and Harvest should be considered,
although not statistically significant in all conditions.
Analysis of heterogeneous error variance in the first trial
We then analyzed which factor affected within-individual
error. Because two laboratory members were involved in
each step of this experiment, we assumed that within-
individual error, i.e. error variance, could be different
depending on the personnel in each step. Thus, we chose
a fixed-effect model with heterogeneous variance of error
affected by Harvest and ELISA (Table 3).
In Nil condition, difference in error variance was statisti-
cally significant between Harvesters A and B (P = 0.0040),
when error variance caused by ELISA operator was not
considered. Difference of error variance caused by ELISA
operators A and B was also significant (P = 0.024), when
error variance caused by Harvester was not taken into
account. These findings imply that under the model, the
error variance was affected significantly by different Har-
vesters or ELISA operators, respectively.
Intervention
By means of the above-mentioned statistical analysis of
the first trial, we identified several points to be improved:
a) there was a considerable number of outliers. Within-
individual error was large and between-individual error
CV
Root mean square error
Mean
(%) =× 100
y the first trial
y
ijk i j k ijk
ijk i j
11
2
=+ + + +
=+ + +
μα β γ ε
μα β γ
()
&& & &
k k ijk the second trial +ε 2()
Table 2: Three-way analysis of variance in the first trial.
Nil TB-Antigen Mitogen
Mean (IU/ml) 0.7821 5.4013 15.3638
Harvest
Mean Square 0.0000 1.5252 51.2656
F value 0.0000 0.2200 2.5600
P value 0.9984 0.6482 0.1404
ELISA
Mean Square 1.8838 12.3026 161.3535
F value 1.2600 1.7800 8.0700
P value 0.2847 0.2112 0.0175
Error
Mean Square 1.4741 6.8935 19.9916
Root Mean Square 1.2142 2.6255 4.4712
Coefficient of Variation (%) 155.2476 48.6099 29.1022BMC Infectious Diseases 2009, 9:66 http://www.biomedcentral.com/1471-2334/9/66
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was also comparably large, and b) within-individual error
was affected by both Harvesters and ELISA operators at
least when Nil was measured.
Based on these results, an intervention was introduced: 1)
reviewing all procedures of Harvest and ELISA, 2) recon-
sidering and strengthening standard operation proce-
dures, 3) checking working condition of machines, and 4)
developing a checklist for countercheck. First, we
attempted to find out which procedure of harvesting and
ELISA operation would be unstable and all questionable
manipulations were listed up. Essential laboratory skills,
such as mixing the solution by pipetting, were reviewed.
Secondly, standard operation procedures were rechecked
and corrected seeing that the laboratory personnel were
handling three blood collection tubes and three other
plasma storage tubes from each blood donor at a time,
they should take every care to identify the tubes during
Harvest and ELISA and to confirm the right position of
corresponding tubes. Thorough instruction for handling
ELISA plates and tubes with manipulation of the pipette
was given to avoid carry-over error or contamination.
After intensive discussions, more attention was paid to
basic laboratory practice and reduction of preventable
mistakes. Thirdly, performance of the ELISA plate washer
and reader and the quality of distilled water were also
checked. Technical requirements from the manufacturer,
such as temperature for reagent reservation, time of incu-
bation, were strictly followed. Finally, a checklist for the
countercheck of each step was developed for practical use.
General assessment by CV before and after intervention
To assess the overall improvement after intervention, CV
was compared between the two trials. Because variation
due to Harvest and ELISA was of interest, CV adjusted by
the effect of specimens was calculated and used. The CV
had decreased remarkably in each condition of the second
trial, as compared with that of the first trial, indicating the
overall improvement of test performance after interven-
tion (Table 4).
Evaluation of outliers and three-way ANOVA in the second 
trial
In the second trial, only one outlier was seen in Nil condi-
tion (Mahalanobis D = 2.59); the number of outliers was
lower than that of the first trial.
We then proceeded to analyze the change of parameters
that had possibly contributed to overall improvement of
test performance. As shown in Table 5, both mean square
error and mean-square values showing effects of Harvest
and of ELISA were markedly lower in the second trial. The
former implies the decrease in within-individual error and
the latter shows the reduction of between-individual
error. The latter change was also clearly shown when dif-
ferences of least square means between Harvesters and
between ELISA operators in each condition of the second
trial were compared with those in the first trial (Figure 1).
Analysis of heterogeneous error variance affected by 
harvester and ELISA operator in the second trial
In contrast to the first trial, there were no significant dif-
ferences of error variance affected by Harvesters or ELISA
operators (Table 6). This finding showed that the hetero-
geneous error variance indicating personnel-dependent
unstableness was small enough in each step of the second
trial.
Assessment of heterogeneous variance between the two 
trials
We further evaluated the decrease in overall within-indi-
vidual error statistically. For this purpose, we used a fixed-
effect model with heterogeneous variance between the
two trials. Under the assumption that influence of Harvest
and ELISA was not changed between the two trials, esti-
mated overall error variances of the two trials were com-
Table 3: Error variance affected by Harvester (left) and error variance affected by ELISA operator (right) in the first trial.
εi.H a r v e s t e r P value ε.j ELISA operator P value
Nil A:1.9150
B:0.0160
0.0040 Nil A:0.0036
B:3.2723
0.0244
TB-Antigen A:2.9897
B:9.7114
0.2546 TB-Antigen A: 0.1270
B:15.2216
0.0830
Mitogen A:33.5782
B: 5.6792
0.2780 Mitogen A:41.1154
B: 3.0221
0.3584
Table 4: CV adjusted by specimen in the two trials.
CV (%)
Condition 1st trial 2nd trial
Nil 150.5036 2.1661
TB-Antigen 48.6219 2.3967
Mitogen 38.1630 9.8776BMC Infectious Diseases 2009, 9:66 http://www.biomedcentral.com/1471-2334/9/66
Page 6 of 8
(page number not for citation purposes)
pared. As shown in Table 7, values indicating the overall
within-individual error in all conditions had significantly
decreased in the second trial (P < 0.0001).
Discussion
We have demonstrated that a study design BIBD and sta-
tistical analysis using fixed-effect models with heterogene-
ous variance of error are useful for objective and
quantitative assessment of laboratory testing for the first
time. A series of experiments in our study clearly showed
that proficiency of the personnel was improved by an
appropriate intervention between the first and second tri-
als of a two-step ELISA-based immunoassay for tuberculo-
sis newly introduced to a resource-constrained laboratory.
Design of clinical experiments including block designs
can be used to estimate effect of factors and their possible
interaction [10]. In block designs including BIBD, intro-
duction of blocks usually provides extra precision for
comparison of other factors, while difference between
blocks is of no intrinsic interest [10]. In our proficiency
testing, variation of individual specimens was not the
point of interest, but analysis of the other two factors, Har-
vest and ELISA was of importance. Roles of laboratory
members are occasionally changed because of limited
manpower. In such a case, our analysis is indispensable
for assessment of their individual skills in each step of the
testing, since this kind of approach has not been evaluated
by the conventional IQC methods [11].
Previous studies in clinical fields other than laboratory
medicine showed the advantage of BIBD over the sample
size [12-14]. In the present study, this design enabled us
to evaluate essential components of the blood testing pro-
cedure systematically without collecting an extra speci-
men from each donor. If all combinations of Harvesters
and ELISA operators were to be tested at the same time, a
twice-larger volume of blood should be collected from
each volunteer, however, obtaining consent of this often
causes difficulties in a country where blood sampling is
not easily accepted. We have shown furthermore that this
design is suitable for clinical settings in which many dif-
ferent specimens are to be handled at the same time.
In the first trial before intervention, we found that within-
individual error was large and between-individual error
tended to be so. However, a number of outliers also
affected both within- and between-individual errors. The
cause of outliers was probably due to mixing up of speci-
Table 5: Three-way analysis of variance in the second trial.
Nil TB-Antigen Mitogen
Mean (IU/ml) 0.2308 0.3071 11.0017
Harvest
Mean Square 0.0000 0.0000 3.4225
F value 1.0000 0.1000 3.2100
P value 0.3409 0.7572 0.1036
ELISA
Mean Square 0.0000 0.0000 0.0770
F value 1.0000 0.4000 0.0700
P value 0.3409 0.5393 0.7937
Error
Mean Square 0.0000 0.0001 1.1707
Root Mean Square 0.0050 0.0079 1.0330
Coefficient of Variation (%) 2.1661 2.5615 9.3898
Least square means of measurements in the first and the second trials Figure 1
Least square means of measurements in the first and the second trials. Differences in least square means between 
Harvesters and between ELISA operators in the conditions of Nil, TB-Antigen and Mitogen in the second trial were compared 
with those in the first trial.
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men tubes or contamination of samples resulting from
unfamiliar handling of multiple samples, although this
was not easily determined [15,16]. Using a fixed-effect
model with the heterogeneity of error variance, we further
illustrated that within-individual error was affected by
Harvesters and ELISA operators. The results indicated that
there were problems with both steps of Harvest and
ELISA, and with both laboratory members, and this repre-
sented a strong motivation to improve the skills of the lab-
oratory personnel in both steps of Harvest and ELISA.
After timely intervention including checkup of all steps
and standard operation procedures, marked improve-
ment was observed in all parameters including CV, a gen-
eral parameter for precision of measurements [8]. In case
of IGRA in this study, CV should be kept less than 10%
[17,18] and in the second trial, this criterion was met sat-
isfactorily.
We propose as a consequence the following action plan to
improve diagnostic capacity in resource-constrained set-
tings. This could be generalized not only for complicated
immunoassay for infectious disease but also for other
kinds of clinical tests:
￿ Set the target CV derived from simple one-way
ANOVA model of specimen (for example, 10%). This
value should be defined before the commencement of
study.
￿ Design experiment to evaluate between- and within-
individual error.
￿ Conduct experiment.
￿ Analyze data with ANOVA model with and without
heterogeneous error variance.
￿ If CV exceeds the target, review the operating proce-
dures.
￿ Conduct experiment a second time.
￿ Consequently analyze data to ascertain any improve-
ment.
￿ Return to step 5 until CV becomes less than the tar-
get.
In-house quality control for effective transfer of skills is a
topic of interest in our proposal and this should be carried
out easily, at a low cost, whilst assuring objective and
quantitative assessment in a clinical laboratory where
resources such as reagents, manpower and feasibility of
sample collection are limited. Our plan meets the above
requirement. Measurements could be sent via the internet
and analyzed in a statistical way by a joint-research facility
inside or outside the country and an immediate feedback
should be sent in an appropriate manner. Such continu-
ous efforts to share information are important to main-
tain quality levels over a long distance [19].
In this age of evidence-based medicine and development
of new diagnostic technologies, quality of laboratory tests
is essential. There is an urgent need for validation and
standardization of the new assays before they are adopted
into clinical diagnostics [20]. Until such time as an effec-
tive quality control system is established, our approach is
valuable to assure the quality of laboratory tests for timely
diagnosis and treatment of infectious diseases. Another
favorable design or analytical method might be suggested
by others in the future studies, seeing that no standard
way of quality monitoring has been proposed so far. We
expect that the successful experience gathered in the
present study will provide useful information for further
comparison and discussion.
Table 6: Error variance affected by Harvester (left) and error variance affected by ELISA operator (right) in the second trial.
εi.H a r v e s t e r P value ε.j ELISA operator P value
Nil NE* (A > B) Nil A:0.000014
B:0.000035
0.4832
TB-Antigen A:0.0001
B:0.00002
0.2391 TB-Antigen NE (A > B)
Mitogen A:2.1184
B: 0.1788
0.3291 Mitogen A:1.9065
B: 0.2747
0.33347
*NE = not estimable by this calculation.
Table 7: Difference in estimated overall within-individual error 
between the two trials.
Estimated overall error variance (εijk)
Condition 1st trial 2nd trial*
Nil 1.3866 0.000025
TB-Antigen 6.9003 0.000062
Mitogen 35.3152 1.0814
*P < 0.0001BMC Infectious Diseases 2009, 9:66 http://www.biomedcentral.com/1471-2334/9/66
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Our study has some limitations. It was obvious that out-
liers influenced statistical analysis in the first trial and
exact causes of error in each condition were not clearly
specified by the present analysis itself [15]. Through
repeated experiments, the causes of error might be clearer,
although all errors in our study decreased dramatically
after a single intervention. We should also emphasize in
conclusion, that a number of procedures should be com-
bined to establish a total quality assurance system.
Conclusion
In a setting where a modern quality control system has
not been entirely established, a laboratory test could be
assessed quantitatively and such objective assessment is
helpful for quality improvement of the test, if an appro-
priate design of experiment and statistical method are
chosen. The design of experiment BIBD and analytical
models for ANOVA were useful for objective assessment
of individual skills in each stage of a multi-step immu-
noassay for tuberculosis in a laboratory with limited
resources. A proposed plan to assess the level of profi-
ciency might be useful for skill improvement of clinical
testing especially for infectious diseases when monitoring
is difficult to assure the sustainability of the technology
transferred.
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